2022 Q4 Form 10-Q Financial Statement
#000162828022027479 Filed on November 01, 2022
Income Statement
Concept | 2022 Q4 | 2022 Q3 |
---|---|---|
Revenue | $18.82M | $18.98M |
YoY Change | 22.19% | 31.72% |
Cost Of Revenue | $4.160M | $6.506M |
YoY Change | -18.03% | 17.06% |
Gross Profit | $14.66M | $12.47M |
YoY Change | 41.95% | 40.93% |
Gross Profit Margin | 77.89% | 65.72% |
Selling, General & Admin | $24.14M | $24.95M |
YoY Change | -3.79% | -36.45% |
% of Gross Profit | 164.67% | 200.05% |
Research & Development | $33.03M | $29.14M |
YoY Change | 19.62% | 15.05% |
% of Gross Profit | 225.36% | 233.63% |
Depreciation & Amortization | $92.00K | $105.0K |
YoY Change | -39.87% | -31.37% |
% of Gross Profit | 0.63% | 0.84% |
Operating Expenses | $57.17M | $60.60M |
YoY Change | 8.48% | -13.61% |
Operating Profit | -$42.51M | -$41.62M |
YoY Change | 0.32% | -25.33% |
Interest Expense | -$13.43M | $14.15M |
YoY Change | -0.01% | 3.65% |
% of Operating Profit | ||
Other Income/Expense, Net | $455.0K | $659.0K |
YoY Change | -88.45% | 4969.23% |
Pretax Income | -$55.49M | -$55.12M |
YoY Change | -14.79% | -20.56% |
Income Tax | $0.00 | |
% Of Pretax Income | ||
Net Earnings | -$55.49M | -$55.12M |
YoY Change | -14.79% | -20.56% |
Net Earnings / Revenue | -294.86% | -290.4% |
Basic Earnings Per Share | -$0.81 | |
Diluted Earnings Per Share | -$0.75 | -$0.81 |
COMMON SHARES | ||
Basic Shares Outstanding | 73.68M shares | 66.55M shares |
Diluted Shares Outstanding | 67.81M shares |
Balance Sheet
Concept | 2022 Q4 | 2022 Q3 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $166.9M | $189.3M |
YoY Change | -35.66% | 82.63% |
Cash & Equivalents | $124.8M | $159.4M |
Short-Term Investments | $42.09M | $29.94M |
Other Short-Term Assets | $10.89M | $11.41M |
YoY Change | -11.53% | 0.85% |
Inventory | $35.20M | $29.55M |
Prepaid Expenses | ||
Receivables | $33.73M | $31.49M |
Other Receivables | $0.00 | $0.00 |
Total Short-Term Assets | $246.7M | $261.8M |
YoY Change | -25.01% | 53.39% |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | $164.0K | $256.0K |
YoY Change | -75.3% | -68.67% |
Goodwill | ||
YoY Change | ||
Intangibles | $56.00K | |
YoY Change | 0.0% | |
Long-Term Investments | ||
YoY Change | ||
Other Assets | $0.00 | $50.00M |
YoY Change | -100.0% | 0.0% |
Total Long-Term Assets | $1.256M | $51.04M |
YoY Change | -97.61% | -6.5% |
TOTAL ASSETS | ||
Total Short-Term Assets | $246.7M | $261.8M |
Total Long-Term Assets | $1.256M | $51.04M |
Total Assets | $247.9M | $312.8M |
YoY Change | -35.02% | 38.88% |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $23.04M | $18.58M |
YoY Change | 31.21% | -10.44% |
Accrued Expenses | $41.00M | $40.08M |
YoY Change | 5.63% | -1.33% |
Deferred Revenue | $3.507M | $4.045M |
YoY Change | -38.29% | 31.84% |
Short-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Long-Term Debt Due | ||
YoY Change | ||
Total Short-Term Liabilities | $92.31M | $82.35M |
YoY Change | 25.84% | 4.92% |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $259.9M | $259.5M |
YoY Change | 0.63% | -4.78% |
Other Long-Term Liabilities | $219.5M | $265.1M |
YoY Change | 20450.0% | |
Total Long-Term Liabilities | $479.4M | $524.6M |
YoY Change | 40565.27% | |
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $92.31M | $82.35M |
Total Long-Term Liabilities | $479.4M | $524.6M |
Total Liabilities | $571.7M | $606.9M |
YoY Change | -1.18% | 3.23% |
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$1.340B | -$1.285B |
YoY Change | 21.12% | 23.37% |
Common Stock | $75.00K | $72.00K |
YoY Change | 22.95% | 166.67% |
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | $55.00M | $55.00M |
YoY Change | 0.0% | 0.0% |
Treasury Stock Shares | 1.994M shares | 1.994M shares |
Shareholders Equity | -$323.8M | -$294.1M |
YoY Change | ||
Total Liabilities & Shareholders Equity | $247.9M | $312.8M |
YoY Change | -35.02% | 38.88% |
Cashflow Statement
Concept | 2022 Q4 | 2022 Q3 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | -$55.49M | -$55.12M |
YoY Change | -14.79% | -20.56% |
Depreciation, Depletion And Amortization | $92.00K | $105.0K |
YoY Change | -39.87% | -31.37% |
Cash From Operating Activities | -$42.47M | -$42.83M |
YoY Change | -26.4% | -38.07% |
INVESTING ACTIVITIES | ||
Capital Expenditures | ||
YoY Change | ||
Acquisitions | ||
YoY Change | ||
Other Investing Activities | -$11.79M | $33.00M |
YoY Change | -76.64% | |
Cash From Investing Activities | -$11.79M | $33.00M |
YoY Change | -76.64% | |
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | -30.36M | 46.29M |
YoY Change | -114.23% | 1166.54% |
NET CHANGE | ||
Cash From Operating Activities | -42.47M | -42.83M |
Cash From Investing Activities | -11.79M | 33.00M |
Cash From Financing Activities | -30.36M | 46.29M |
Net Change In Cash | -84.62M | 36.46M |
YoY Change | -180.43% | -155.65% |
FREE CASH FLOW | ||
Cash From Operating Activities | -$42.47M | -$42.83M |
Capital Expenditures | ||
Free Cash Flow | ||
YoY Change |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001434868 | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2022 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
CY2020 | us-gaap |
Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
|
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member | |
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2022-09-30 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
001-35986 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
Esperion Therapeutics, Inc. | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
26-1870780 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
3891 Ranchero Drive, Suite 150 | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Ann Arbor | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MI | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
48108 | ||
dei |
City Area Code
CityAreaCode
|
734 | ||
dei |
Local Phone Number
LocalPhoneNumber
|
887-3903 | ||
dei |
Security12b Title
Security12bTitle
|
Common Stock, par value $0.001 per share | ||
dei |
Trading Symbol
TradingSymbol
|
ESPR | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
false | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2022Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
73683572 | shares |
CY2022Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
159399000 | usd |
CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
208892000 | usd |
CY2022Q3 | us-gaap |
Short Term Investments
ShortTermInvestments
|
29942000 | usd |
CY2021Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
50441000 | usd |
CY2022Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
31489000 | usd |
CY2021Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
22934000 | usd |
CY2022Q3 | espr |
Prepaid Clinical Development Costs Current
PrepaidClinicalDevelopmentCostsCurrent
|
2199000 | usd |
CY2021Q4 | espr |
Prepaid Clinical Development Costs Current
PrepaidClinicalDevelopmentCostsCurrent
|
1138000 | usd |
CY2022Q3 | us-gaap |
Inventory Net
InventoryNet
|
29545000 | usd |
CY2021Q4 | us-gaap |
Inventory Net
InventoryNet
|
34394000 | usd |
CY2022Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
9211000 | usd |
CY2021Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
11173000 | usd |
CY2022Q3 | us-gaap |
Assets Current
AssetsCurrent
|
261785000 | usd |
CY2021Q4 | us-gaap |
Assets Current
AssetsCurrent
|
328972000 | usd |
CY2022Q3 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
50000000 | usd |
CY2021Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
50000000 | usd |
CY2022Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
256000 | usd |
CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
664000 | usd |
CY2022Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
730000 | usd |
CY2021Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1898000 | usd |
CY2022Q3 | us-gaap |
Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
|
56000 | usd |
CY2021Q4 | us-gaap |
Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
|
56000 | usd |
CY2022Q3 | us-gaap |
Assets
Assets
|
312827000 | usd |
CY2021Q4 | us-gaap |
Assets
Assets
|
381590000 | usd |
CY2022Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
18580000 | usd |
CY2021Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
17559000 | usd |
CY2022Q3 | espr |
Accrued Clinical Development Costs Current
AccruedClinicalDevelopmentCostsCurrent
|
3996000 | usd |
CY2021Q4 | espr |
Accrued Clinical Development Costs Current
AccruedClinicalDevelopmentCostsCurrent
|
7013000 | usd |
CY2022Q3 | espr |
Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
|
35395000 | usd |
CY2021Q4 | espr |
Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
|
30410000 | usd |
CY2022Q3 | espr |
Revenue Interest Liability Current
RevenueInterestLiabilityCurrent
|
19636000 | usd |
CY2021Q4 | espr |
Revenue Interest Liability Current
RevenueInterestLiabilityCurrent
|
11295000 | usd |
CY2022Q3 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
4045000 | usd |
CY2021Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
5683000 | usd |
CY2022Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
693000 | usd |
CY2021Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
1392000 | usd |
CY2022Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
82345000 | usd |
CY2021Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
73352000 | usd |
CY2022Q3 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
259487000 | usd |
CY2021Q4 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
258280000 | usd |
CY2022Q3 | espr |
Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
|
265048000 | usd |
CY2021Q4 | espr |
Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
|
245744000 | usd |
CY2022Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
47000 | usd |
CY2021Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
524000 | usd |
CY2022Q3 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
0 | usd |
CY2021Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
634000 | usd |
CY2022Q3 | us-gaap |
Liabilities
Liabilities
|
606927000 | usd |
CY2021Q4 | us-gaap |
Liabilities
Liabilities
|
578534000 | usd |
CY2022Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2021Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2021Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2022Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2022Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2022Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2021Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2022Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2021Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2022Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
CY2021Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
CY2022Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2021Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2022Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
240000000 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
120000000 | shares |
CY2022Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
73739320 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
62873694 | shares |
CY2022Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
72000 | usd |
CY2021Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
61000 | usd |
CY2022Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
1045468000 | usd |
CY2021Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
964401000 | usd |
CY2021Q4 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
1994198 | shares |
CY2022Q3 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
1994198 | shares |
CY2022Q3 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
54998000 | usd |
CY2021Q4 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
54998000 | usd |
CY2022Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-93000 | usd |
CY2021Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-31000 | usd |
CY2022Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1284549000 | usd |
CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1106377000 | usd |
CY2022Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-294100000 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-196944000 | usd |
CY2022Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
312827000 | usd |
CY2021Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
381590000 | usd |
CY2022Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
18980000 | usd |
CY2021Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
14409000 | usd |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
56657000 | usd | |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
63046000 | usd | |
CY2022Q3 | us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
6506000 | usd |
CY2021Q3 | us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
5558000 | usd |
us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
22807000 | usd | |
us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
9142000 | usd | |
CY2022Q3 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
29143000 | usd |
CY2021Q3 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
25331000 | usd |
us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
85894000 | usd | |
us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
78359000 | usd | |
CY2022Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
24954000 | usd |
CY2021Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
39265000 | usd |
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
84944000 | usd | |
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
146647000 | usd | |
CY2022Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
60603000 | usd |
CY2021Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
70154000 | usd |
us-gaap |
Operating Expenses
OperatingExpenses
|
193645000 | usd | |
us-gaap |
Operating Expenses
OperatingExpenses
|
234148000 | usd | |
CY2022Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-41623000 | usd |
CY2021Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-55745000 | usd |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-136988000 | usd | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-171102000 | usd | |
CY2022Q3 | us-gaap |
Interest Expense
InterestExpense
|
14153000 | usd |
CY2021Q3 | us-gaap |
Interest Expense
InterestExpense
|
13654000 | usd |
us-gaap |
Interest Expense
InterestExpense
|
42481000 | usd | |
us-gaap |
Interest Expense
InterestExpense
|
32923000 | usd | |
CY2022Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
659000 | usd |
CY2021Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
13000 | usd |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1297000 | usd | |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
36000 | usd | |
CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-55117000 | usd |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-69386000 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-178172000 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-203989000 | usd | |
CY2022Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.81 | |
CY2022Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.81 | |
CY2021Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-2.62 | |
CY2021Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-2.62 | |
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-2.78 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-2.78 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-7.78 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-7.78 | ||
CY2022Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
67806292 | shares |
CY2022Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
67806292 | shares |
CY2021Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
26455209 | shares |
CY2021Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
26455209 | shares |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
64021248 | shares | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
64021248 | shares | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
26225730 | shares | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
26225730 | shares | |
CY2022Q3 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
204000 | usd |
CY2021Q3 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
0 | usd |
us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-62000 | usd | |
us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
0 | usd | |
CY2022Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-54913000 | usd |
CY2021Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-69386000 | usd |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-178234000 | usd | |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-203989000 | usd | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-96134000 | usd |
CY2021Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
2668000 | usd |
CY2021Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
1183000 | usd |
CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5751000 | usd |
CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-90935000 | usd |
CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-269394000 | usd |
CY2021Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
168000 | usd |
CY2021Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
8584000 | usd |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-43668000 | usd |
CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-304310000 | usd |
CY2021Q3 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
4207000 | usd |
CY2021Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
375000 | usd |
CY2021Q3 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
912000 | usd |
CY2021Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5497000 | usd |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-69386000 | usd |
CY2021Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-362705000 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-196944000 | usd |
CY2022Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
431000 | usd |
CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4436000 | usd |
CY2022Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-232000 | usd |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-56731000 | usd |
CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-249040000 | usd |
CY2022Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3527000 | usd |
CY2022Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
20173000 | usd |
CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-34000 | usd |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-66324000 | usd |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-291698000 | usd |
CY2022Q3 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
301000 | usd |
CY2022Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3537000 | usd |
CY2022Q3 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
48673000 | usd |
CY2022Q3 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
204000 | usd |
CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-55117000 | usd |
CY2022Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-294100000 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-178172000 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-203989000 | usd | |
us-gaap |
Depreciation
Depreciation
|
408000 | usd | |
us-gaap |
Depreciation
Depreciation
|
459000 | usd | |
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-539000 | usd | |
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
0 | usd | |
us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
1207000 | usd | |
us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
1214000 | usd | |
espr |
Non Cash Interest Expense Related To Revenue Interest Liability
NonCashInterestExpenseRelatedToRevenueInterestLiability
|
33323000 | usd | |
espr |
Non Cash Interest Expense Related To Revenue Interest Liability
NonCashInterestExpenseRelatedToRevenueInterestLiability
|
23310000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
11500000 | usd | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
19832000 | usd | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
8555000 | usd | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
9322000 | usd | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-901000 | usd | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1096000 | usd | |
us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-2272000 | usd | |
us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
2251000 | usd | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-4849000 | usd | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
17836000 | usd | |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1129000 | usd | |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-30833000 | usd | |
us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
2788000 | usd | |
us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
7715000 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-132355000 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-206103000 | usd | |
us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
18102000 | usd | |
us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
0 | usd | |
us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
38000000 | usd | |
us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
0 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
19898000 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
0 | usd | |
espr |
Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs
ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts
|
0 | usd | |
espr |
Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs
ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts
|
49917000 | usd | |
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | usd | |
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
3211000 | usd | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
68861000 | usd | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
4388000 | usd | |
espr |
Payments From Revenue Interest Purchase Agreement
PaymentsFromRevenueInterestPurchaseAgreement
|
5678000 | usd | |
espr |
Payments From Revenue Interest Purchase Agreement
PaymentsFromRevenueInterestPurchaseAgreement
|
2263000 | usd | |
us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
219000 | usd | |
us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
440000 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
62964000 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
54813000 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-49493000 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-151290000 | usd | |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
258892000 | usd |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
304962000 | usd |
CY2022Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
209399000 | usd |
CY2021Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
153672000 | usd |
espr |
Common Stock Issuance Costs Incurred
CommonStockIssuanceCostsIncurred
|
15000 | usd | |
espr |
Common Stock Issuance Costs Incurred
CommonStockIssuanceCostsIncurred
|
181000 | usd | |
espr |
Non Cash Right Of Use Asset
NonCashRightOfUseAsset
|
8000 | usd | |
espr |
Non Cash Right Of Use Asset
NonCashRightOfUseAsset
|
10000 | usd | |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div> | ||
CY2022Q3 | us-gaap |
Restricted Cash
RestrictedCash
|
50000000 | usd |
CY2022Q3 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
179192000 | usd |
us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of September 30, 2022, thirteen customers accounted for all of the Company's net trade receivables and as of December 31, 2021, nine customers accounted for all the Company's net trade receivables.</span></div> | ||
espr |
Number Of Sources Of Revenue
NumberOfSourcesOfRevenue
|
2 | revenue_source | |
CY2022Q3 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
24785000 | usd |
CY2021Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
31850000 | usd |
CY2022Q3 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
2874000 | usd |
CY2021Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
663000 | usd |
CY2022Q3 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
1886000 | usd |
CY2021Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
1881000 | usd |
CY2022Q3 | us-gaap |
Inventory Net
InventoryNet
|
29545000 | usd |
CY2021Q4 | us-gaap |
Inventory Net
InventoryNet
|
34394000 | usd |
CY2022Q3 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
179285000 | usd |
CY2022Q3 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
0 | usd |
CY2022Q3 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
93000 | usd |
CY2021Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
239606000 | usd |
CY2021Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
0 | usd |
CY2021Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
31000 | usd |
CY2021Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
239575000 | usd |
CY2022Q3 | us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
|
0 | usd |
CY2021Q3 | us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
|
0 | usd |
CY2022Q3 | us-gaap |
Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
|
200000 | usd |
espr |
Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
|
0 | usd | |
CY2022Q3 | espr |
Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
|
0 | usd |
CY2021Q3 | espr |
Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
|
0 | usd |
espr |
Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
|
0 | usd | |
CY2020Q4 | us-gaap |
Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
|
46000000 | usd |
CY2020Q4 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
55000000 | usd |
CY2020Q4 | us-gaap |
Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
|
46000000 | usd |
CY2020Q4 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
55000000 | usd |
CY2020Q4 | us-gaap |
Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
|
1994198 | shares |
us-gaap |
Stock Issued During Period Shares Treasury Stock Reissued
StockIssuedDuringPeriodSharesTreasuryStockReissued
|
71174 | shares | |
CY2022Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
8512000 | usd |
CY2021Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
8809000 | usd |
CY2022Q3 | espr |
Accrued Variable Consideration Current
AccruedVariableConsiderationCurrent
|
20525000 | usd |
CY2021Q4 | espr |
Accrued Variable Consideration Current
AccruedVariableConsiderationCurrent
|
16192000 | usd |
CY2022Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
2344000 | usd |
CY2021Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
3917000 | usd |
CY2022Q3 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
3975000 | usd |
CY2021Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
1325000 | usd |
CY2022Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
39000 | usd |
CY2021Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
167000 | usd |
CY2022Q3 | espr |
Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
|
35395000 | usd |
CY2021Q4 | espr |
Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
|
30410000 | usd |
CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3214537 | shares |
CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
38.38 | |
CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P4Y2M4D | |
CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
0 | usd |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1255600 | shares | |
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
4.78 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
685182 | shares | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
33.01 | ||
us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | shares | |
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | ||
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3784955 | shares |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
28.20 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P5Y2M4D | ||
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
2098000 | usd |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
3784955 | shares |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
28.20 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P5Y2M4D | ||
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
2098000 | usd |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
2421198 | shares |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
38.23 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P2Y10M28D | ||
CY2022Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
163000 | usd |
CY2022Q3 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
9.00 | |
CY2021Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
9.00 | |
CY2021Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
CY2022Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd | |
CY2021Q4 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
36964286 | shares |
CY2021Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
9.00 | |
CY2021Q4 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
61900000 | usd |
CY2022Q3 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
36964286 | shares |
CY2021Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
36964286 | shares |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
51380538 | shares | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
13098695 | shares | |
CY2022Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
159399000 | usd |
CY2021Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
103672000 | usd |
CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
208892000 | usd |
CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
304962000 | usd |
CY2022Q3 | us-gaap |
Restricted Cash
RestrictedCash
|
50000000 | usd |
CY2021Q3 | us-gaap |
Restricted Cash
RestrictedCash
|
50000000 | usd |
CY2021Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
50000000 | usd |
CY2020Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
0 | usd |
CY2022Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
209399000 | usd |
CY2021Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
153672000 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
258892000 | usd |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
304962000 | usd |